32386-49-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzylpentanedioic acid is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable building block for the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
3-Benzylpentanedioic acid is used as a reagent in chemical synthesis processes. Its dicarboxylic acid functionality allows for the formation of esters, amides, and other derivatives, which can be further utilized in the production of specialty chemicals and materials.
Used in Research and Development:
3-Benzylpentanedioic acid is used as a research compound in the study of its pharmacological and therapeutic properties. Scientists are investigating its potential applications in medicine and exploring its biological effects to better understand its role in various biological processes.

Upstream product

• 176972-48-8 4-benzylcyclohexanol 
• 122-78-1 phenylacetaldehyde 
• 86103-46-0 2-benzylpropane-1,3-diyl bis(4-methylbenzenesulfonate) 
• 2612-30-8 2-benzyl-1,3-propanediol 
• 607-81-8 diethyl 2-benzylmalonate 
• 2243-53-0 styrylacetic acid 
• 5629-57-2 ethyl cinnamate 
• 101-53-1 p-benzylphenol 
• 91963-19-8 3-benzyl-glutaric acid-anhydride 
• 5386-93-6 3-benzyl-2-cyano-glutaric acid diethyl ester 
• 151-50-8 potassium cyanide 
• 109-89-7 diethylamine 
• 105-53-3 diethyl malonate 
• 861542-23-6 3-benzyl-2,4-dicyano-glutaric acid 

Downstream Products

• 91963-19-8 3-benzyl-glutaric acid-anhydride 

Relevant academic research and scientific papers

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

Structure-activity relationships of imidazole-derived 2-[ N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme

Insulin degrading enzyme (IDE) is a zinc metalloprotease that degrades small amyloid peptides such as amyloid-a and insulin. So far the dearth of IDE-specific pharmacological inhibitors impacts the understanding of its role in the physiopathology of Alzheimer's disease, amyloid-a clearance, and its validation as a potential therapeutic target. Hit 1 was previously discovered by high-throughput screening. Here we describe the structure-activity study, that required the synthesis of 48 analogues. We found that while the carboxylic acid, the imidazole and the tertiary amine were critical for activity, the methyl ester was successfully optimized to an amide or a 1,2,4-oxadiazole. Along with improving their activity, compounds were optimized for solubility, lipophilicity and stability in plasma and microsomes. The docking or co-crystallization of some compounds at the exosite or the catalytic site of IDE provided the structural basis for IDE inhibition. The pharmacokinetic properties of best compounds 44 and 46 were measured in vivo. As a result, 44 (BDM43079) and its methyl ester precursor 48 (BDM43124) are useful chemical probes for the exploration of IDE's role.